Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06049108 · ClinicalTrials.gov registry record · Phase 1
A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06049108 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 8 participants.
The verdict
NCT06049108, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate how much of the study drug (LY3871801), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks including the screening period.
Interventions
- DRUG [14C]-LY3871801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2023-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06049108
The ClinicalTrials.gov registry entry for NCT06049108 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-LY3871801 is the first listed.
NCT06049108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06049108 about?
NCT06049108 is a clinical study titled "A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants". The main purpose of this study is to evaluate how much of the study drug (LY3871801), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of t...
What is the current status of trial NCT06049108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-09-15. Estimated completion is 2023-11-03.
What interventions are being tested in trial NCT06049108?
The interventions under investigation include: [14C]-LY3871801 (DRUG).
Who is sponsoring clinical trial NCT06049108?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.